Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

NCT07185256 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

ARB
BVMD
Autosomal-Dominant Bestrophinopathy
Best Vitelliform Macular Dystrophy

Interventions

GENETIC: OPGx-BEST1

Sponsor

Opus Genetics, Inc